Business
TNI BioTech Announces Results of Annual Shareholders Meeting
TNI BioTech Announces Results of Annual Shareholders Meeting.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nTNI BioTech Announces Results of Annual Shareholders Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTNI BioTech Announces Results of Annual Shareholders Meeting\nPR Newswire\nORLANDO, Fla. and DUBLIN, Sept. 9, 2014\n\n\n\nORLANDO, Fla. and DUBLIN, Sept. 9, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC-BB: TNIB) (\"we\" or the \"Company\"), a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced the results of its 2014 annual general meeting of shareholders.\n\nThe shareholders of the Company have approved all the matters submitted to them at the Company's 2014 annual general meeting held at 10:00 a.m., Eastern Daylight Time, on Thursday, September 4, 2014.  A total of 68,872,388 shares were represented in person or by proxy at the Company's 2014 annual general meeting, representing a quorum of approximately 76.24% of the Company's outstanding shares. During the meeting, the following resolutions were duly passed:\n\n(i) Election of members of the Board of Directors, to serve a term until the 2015 Annual Meeting of Shareholders and until their successors are duly elected and qualified;\n\n(ii) Ratification of the appointment of Turner Stone & Company LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014;\n\n(iii) Approval of the Company's 2014 Stock Incentive Plan; and\n\n(iv) Approval of the name change of the Company to Immune Therapeutics, Inc. \n\nMs. Noreen Griffin, the Company's CEO and Chairman, stated, \"On behalf of management, I would like to thank shareholders for their support and confidence in TNI BioTech, Inc. We will continue to focus on enhancing shareholder value through our strategic plan of the manufacturing, marketing and distribution of our immunotherapies for the treatment of cancer, HIV/AIDS and autoimmune diseases in emerging and developing nations.\"  \n\nMs. Griffin announced that in addition to the election of four new members to the Company's Board o...